Exogenous administration of recombinant ORM2 or long-acting ORM2-IgG Fc has been shown to attenuate hepatic steatosis, steatohepatitis, hyperlipidemia, and atherosclerosis in preclinical mouse models (Li et al., 2023; Zhou et al., 2022). This evidence concerns the gene ORM2 and hyperlipidemia.